| Literature DB >> 25478876 |
Ai Koyanagi1, Noe Garin1, Beatriz Olaya1, Jose Luis Ayuso-Mateos2, Somnath Chatterji3, Matilde Leonardi4, Seppo Koskinen5, Beata Tobiasz-Adamczyk6, Josep Maria Haro1.
Abstract
BACKGROUND: Data on the association between chronic conditions or the number of chronic conditions and sleep problems in low- or middle-income countries is scarce, and global comparisons of these associations with high-income countries have not been conducted.Entities:
Mesh:
Year: 2014 PMID: 25478876 PMCID: PMC4257709 DOI: 10.1371/journal.pone.0114742
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of the study sample.
| COURAGE study | SAGE study | |||||||||
| Overall | Finland | Poland | Spain | China | Ghana | India | Mexico | Russia | S. Africa | |
| Age (years) | ||||||||||
| 50–59 | 44.9 (0.7) | 33.3 (1.2) | 38.3 (1.3) | 32.2 (1.1) | 44.9 (1.2) | 39.7 (1.1) | 48.6 (1.0) | 48.1 (4.1) | 45.2 (2.4) | 49.9 (1.6) |
| 60–69 | 30.1 (0.5) | 35.4 (1.4) | 32.9 (1.3) | 28.2 (0.8) | 31.9 (0.6) | 27.5 (0.8) | 30.9 (0.9) | 25.6 (2.7) | 24.6 (1.3) | 30.6 (1.2) |
| 70–79 | 19.0 (0.5) | 20.0 (1.0) | 19.9 (1.1) | 29.3 (1.2) | 18.6 (0.9) | 23.1 (0.9) | 16.0 (0.8) | 17.8 (1.9) | 21.8 (1.6) | 14.0 (0.9) |
| ≥80 | 6.0 (0.2) | 11.2 (0.7) | 8.8 (0.5) | 10.3 (0.5) | 4.6 (0.3) | 9.7 (0.6) | 4.5 (0.3) | 8.6 (1.0) | 8.4 (1.0) | 5.5 (0.6) |
| Female | 52.5 (0.5) | 54.0 (1.3) | 56.5 (1.1) | 53.6 (1.2) | 50.2 (0.7) | 47.6 (1.0) | 49.0 (0.6) | 53.2 (3.2) | 61.1 (1.5) | 55.9 (1.5) |
| Education | ||||||||||
| ≥Tertiary | 8.3 (0.6) | 25.9 (2.3) | 15.7 (1.1) | 10.8 (0.9) | 4.5 (0.7) | 3.6 (0.4) | 5.1 (0.6) | 8.1 (1.9) | 18.2 (2.3) | 5.7 (0.8) |
| Secondary | 36.1 (1.2) | 56.9 (1.8) | 59.3 (1.3) | 25.6 (1.6) | 32.5 (1.4) | 21.1 (1.0) | 18.8 (0.9) | 12.3 (2.0) | 74.2 (2.7) | 22.8 (1.5) |
| ≤Primary | 55.6 (1.5) | 17.2 (1.6) | 25.0 (1.2) | 63.6 (2.2) | 63.0 (1.9) | 75.3 (1.2) | 76.1 (1.3) | 79.6 (2.9) | 7.5 (0.9) | 71.4 (1.7) |
| Married/cohabiting | 74.1 (0.8) | 64.7 (1.8) | 68.1 (1.2) | 62.4 (1.1) | 85.0 (0.6) | 59.3 (1.1) | 76.9 (0.8) | 73.0 (3.2) | 58.3 (2.9) | 55.9 (1.5) |
| Current drinker | 22.6 (0.7) | 63.5 (1.8) | 46.8 (1.4) | 46.6 (1.3) | 22.9 (1.0) | 30.6 (1.3) | 6.8 (0.5) | 24.8 (3.8) | 32.7 (2.5) | 13.7 (1.1) |
| Current smoker | 33.2 (0.8) | 17.4 (1.1) | 26.1 (1.3) | 19.8 (0.9) | 29.3 (0.9) | 10.7 (0.7) | 50.0 (1.2) | 20.3 (3.0) | 21.3 (2.0) | 23.8 (1.3) |
| Physical activity | ||||||||||
| High | 47.8 (0.9) | 41.7 (2.1) | 48.6 (1.5) | 30.6 (1.6) | 43.8 (1.6) | 61.5 (1.5) | 52.3 (1.6) | 38.8 (4.7) | 57.3 (2.7) | 27.4 (1.7) |
| Moderate | 23.4 (0.6) | 31.5 (1.4) | 19.6 (1.1) | 37.8 (1.4) | 27.0 (1.1) | 12.5 (0.8) | 22.8 (1.0) | 21.7 (3.2) | 15.6 (1.3) | 11.9 (0.8) |
| Low | 28.8 (0.7) | 26.8 (1.7) | 31.7 (1.5) | 31.6 (1.2) | 29.2 (1.3) | 26.1 (1.4) | 25.0 (1.1) | 39.5 (3.9) | 27.1 (2.2) | 60.7 (1.8) |
Abbreviations: COURAGE Collaborative Research on Ageing in Europe; SAGE WHO Study on global AGEing and adult health; S. Africa South Africa.
Data are % (SE) unless otherwise stated.
Age-adjusted prevalence of severe/extreme sleep problems and chronic conditions among adults aged 50 years or over.
| COURAGE study | SAGE study | |||||||||
| Overall | Finland | Poland | Spain | China | Ghana | India | Mexico | Russia | S. Africa | |
|
| 9.2 (0.4) | 9.6 (0.8) | 17.0 (0.9) | 8.1 (0.8) | 2.8 (0.2) | 7.1 (0.5) | 15.0 (0.9) | 5.8 (1.2) | 9.0 (1.0) | 9.6 (0.7) |
|
| ||||||||||
| Self-reported | 11.3 (0.7) | 9.3 (0.8) | 13.0 (0.9) | 5.3 (0.6) | 7.9 (0.4) | 3.4 (0.3) | 5.5 (0.7) | 2.8 (0.9) | 31.0 (2.3) | 5.2 (0.6) |
| Self-reported and/or symptoms | 16.8 (0.8) | 9.9 (0.7) | 18.3 (1.0) | 6.7 (0.7) | 9.3 (0.4) | 12.4 (0.7) | 17.2 (1.3) | 6.9 (1.2) | 36.0 (2.3) | 8.9 (0.8) |
|
| ||||||||||
| Self-reported | 23.2 (0.6) | 43.6 (1.2) | 30.3 (1.3) | 25.1 (1.2) | 21.8 (0.6) | 13.0 (1.0) | 18.4 (0.9) | 9.0 (1.4) | 29.4 (2.3) | 24.7 (1.4) |
| Self-reported and/or symptoms | 30.1 (0.7) | 47.3 (1.3) | 34.2 (1.4) | 29.1 (1.3) | 26.5 (0.7) | 25.3 (1.2) | 28.0 (0.9) | 14.7 (1.6) | 37.5 (2.6) | 30.6 (1.5) |
|
| ||||||||||
| Self-reported | 4.5 (0.3) | 10.9 (1.0) | 5.6 (0.5) | 6.9 (0.4) | 2.0 (0.1) | 3.1 (0.3) | 7.3 (0.6) | 1.9 (0.3) | 2.7 (0.5) | 4.8 (0.6) |
| Self-reported and/or symptoms | 8.1 (0.4) | 12.9 (1.0) | 9.4 (0.7) | 9.7 (0.6) | 4.3 (0.3) | 4.8 (0.4) | 12.6 (0.8) | 4.9 (0.8) | 6.6 (0.9) | 7.7 (0.7) |
|
| ||||||||||
| Self-reported | 7.6 (0.4) | 3.5 (0.6) | 7.8 (0.6) | 6.7 (0.6) | 8.0 (0.3) | 0.5 (0.1) | 4.5 (0.7) | 3.7 (0.6) | 14.7 (1.4) | 2.9 (0.5) |
| Self-reported and/or symptoms | 9.1 (0.4) | 4.3 (0.7) | 8.7 (0.6) | 7.6 (0.7) | 8.3 (0.3) | 1.2 (0.2) | 8.1 (0.8) | 4.6 (0.7) | 15.1 (1.4) | 4.2 (0.6) |
|
| ||||||||||
| Self-reported | 4.3 (0.3) | 14.8 (0.9) | 11.1 (0.9) | 22.6 (1.1) | 0.3 (0.1) | 1.7 (0.3) | 4.0 (0.5) | 13.5 (2.6) | 3.5 (0.7) | 2.8 (0.4) |
| Self-reported and/or symptoms | 9.4 (0.5) | 16.0 (0.8) | 13.7 (1.0) | 26.4 (1.2) | 1.3 (0.1) | 7.6 (0.7) | 16.0 (0.9) | 16.7 (2.7) | 5.6 (0.8) | 4.7 (0.6) |
|
| ||||||||||
| Self-reported | 7.8 (0.3) | 11.6 (0.9) | 12.7 (0.8) | 14.4 (0.9) | 6.5 (0.3) | 3.8 (0.4) | 6.9 (0.6) | 18.2 (2.0) | 6.9 (0.9) | 9.4 (0.8) |
|
| ||||||||||
| Self-reported | 30.3 (0.8) | 38.0 (1.3) | 50.7 (1.3) | 36.3 (1.1) | 26.7 (0.5) | 13.9 (0.7) | 17.0 (0.8) | 31.3 (2.4) | 51.8 (2.6) | 30.9 (1.6) |
| Self-reported and/or measurement | 56.1 (0.8) | 63.8 (1.5) | 65.8 (1.3) | 58.8 (1.1) | 60.5 (0.8) | 59.5 (1.2) | 37.5 (1.0) | 62.1 (2.7) | 71.1 (2.2) | 78.6 (1.1) |
|
| ||||||||||
| Measurement | 14.4 (0.8) | 26.0 (1.3) | 34.7 (1.4) | 31.0 (1.1) | 5.8 (0.4) | 10.4 (0.7) | 2.5 (0.3) | 28.8 (3.1) | 35.0 (3.0) | 46.3 (1.8) |
|
| ||||||||||
| Self-reported | 3.3 (0.2) | 4.2 (0.6) | 4.5 (0.5) | 3.6 (0.4) | 3.1 (0.2) | 2.6 (0.3) | 2.0 (0.2) | 4.5 (0.9) | 4.5 (0.6) | 4.1 (0.6) |
| Self-reported and/or symptoms | 4.4 (0.3) | 4.5 (0.7) | 5.4 (0.6) | 4.3 (0.5) | 3.7 (0.2) | 3.5 (0.3) | 3.9 (0.4) | 5.8 (0.9) | 6.2 (1.2) | 5.0 (0.7) |
Abbreviations: COURAGE Collaborative Research on Ageing in Europe; SAGE WHO Study on global AGEing and adult health; S. Africa South Africa.
Data are % (SE) unless otherwise stated.
Prevalence of severe/extreme sleep problems by presence of chronic condition and country among adults aged 50 years or over.
| COURAGE study | SAGE study | |||||||||||||||||||
| Overall | Finland | Poland | Spain | China | Ghana | India | Mexico | Russia | S. Africa | |||||||||||
| Chronic condition | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No |
| Anginaa,b,c,d,e,f,g,h,i,j | 19.7 | 7.1 | 22.3 | 7.9 | 36.5 | 13.3 | 19.8 | 8.0 | 6.4 | 2.4 | 13.2 | 6.6 | 27.5 | 11.9 | 12.8 | 5.1 | 16.8 | 5.4 | 21.4 | 8.2 |
| (1.3) | (0.3) | (3.5) | (0.7) | (2.7) | (1.0) | (2.8) | (0.8) | (0.8) | (0.2) | (1.8) | (0.5) | (2.2) | (0.7) | (4.0) | (1.3) | (2.4) | (1.0) | (3.5) | (0.7) | |
| Arthritisa,b,c,d,e,f,g,i,j | 14.7 | 6.9 | 14.4 | 5.0 | 26.5 | 13.0 | 16.5 | 5.3 | 4.3 | 2.2 | 11.3 | 6.0 | 21.3 | 11.9 | 7.4 | 5.3 | 16.1 | 5.7 | 14.3 | 7.3 |
| (0.8) | (0.4) | (1.2) | (0.7) | (1.9) | (1.1) | (1.5) | (0.7) | (0.5) | (0.2) | (1.2) | (0.6) | (1.7) | (0.8) | (1.6) | (1.4) | (2.4) | (0.8) | (1.6) | (0.8) | |
| Asthmaa,b,c,d,e,f,g,i,j | 22.5 | 8.1 | 22.1 | 7.9 | 33.9 | 16.0 | 21.9 | 7.5 | 7.6 | 2.5 | 11.7 | 7.2 | 27.5 | 12.7 | 7.4 | 5.6 | 19.8 | 9.0 | 20.4 | 8.5 |
| (1.8) | (0.4) | (3.3) | (0.6) | (3.8) | (1.0) | (2.3) | (0.7) | (2.1) | (0.2) | (2.3) | (0.6) | (3.3) | (0.7) | (2.4) | (1.3) | (3.8) | (1.1) | (3.9) | (0.7) | |
| Chronic lung diseasea,b,c,d,e,f,g,h,i,j | 17.5 | 8.4 | 17.8 | 9.3 | 36.4 | 15.9 | 24.4 | 7.5 | 5.2 | 2.5 | 25.6 | 7.2 | 23.4 | 13.7 | 11.4 | 5.4 | 18.7 | 8.1 | 29.7 | 8.5 |
| (1.2) | (0.4) | (4.8) | (0.7) | (3.8) | (1.0) | (2.7) | (0.7) | (0.9) | (0.2) | (6.5) | (0.5) | (2.6) | (0.8) | (2.9) | (1.3) | (2.5) | (1.1) | (6.2) | (0.7) | |
| Diabetesa,b,c,d,g,h,i | 14.0 | 8.9 | 14.2 | 9.0 | 23.3 | 16.9 | 12.6 | 8.2 | 3.6 | 2.7 | 8.8 | 7.4 | 21.2 | 14.0 | 11.6 | 4.4 | 15.8 | 9.2 | 12.1 | 9.1 |
| (1.1) | (0.4) | (2.5) | (0.7) | (2.5) | (1.1) | (1.5) | (0.8) | (0.9) | (0.2) | (2.3) | (0.6) | (3.0) | (0.9) | (5.0) | (1.0) | (2.6) | (1.1) | (2.7) | (0.8) | |
| Depressiona,b,c,d,e,f,g,h,i,j | 26.8 | 7.4 | 21.3 | 7.4 | 35.4 | 15.0 | 20.6 | 4.8 | 17.7 | 2.5 | 15.3 | 6.7 | 27.9 | 12.0 | 13.6 | 4.0 | 31.3 | 8.4 | 31.4 | 8.3 |
| (1.3) | (0.4) | (3.1) | (0.7) | (3.1) | (1.0) | (2.0) | (0.5) | (3.5) | (0.2) | (2.7) | (0.6) | (2.1) | (0.9) | (5.2) | (1.2) | (4.1) | (1.0) | (6.3) | (0.7) | |
| Hypertensiona,c,g,h,i | 10.0 | 8.3 | 10.6 | 7.6 | 19.8 | 13.7 | 9.9 | 7.4 | 2.7 | 2.8 | 7.8 | 6.9 | 17.9 | 12.5 | 7.2 | 3.1 | 11.6 | 5.0 | 9.2 | 9.7 |
| (0.5) | (0.5) | (1.0) | (1.1) | (1.2) | (1.5) | (1.0) | (1.0) | (0.2) | (0.3) | (0.7) | (0.7) | (1.2) | (1.0) | (1.8) | (1.0) | (1.4) | (1.1) | (0.8) | (1.5) | |
| Obesity a,c,d | 11.2 | 8.6 | 10.2 | 9.0 | 21.6 | 14.8 | 11.7 | 6.9 | 3.2 | 2.7 | 8.1 | 6.9 | 11.2 | 14.2 | 4.1 | 6.3 | 10.5 | 8.2 | 9.3 | 9.3 |
| (0.9) | (0.4) | (1.6) | (0.8) | (2.0) | (1.1) | (1.4) | (0.7) | (0.7) | (0.2) | (1.6) | (0.5) | (2.9) | (0.8) | (1.0) | (1.9) | (1.9) | (1.2) | (1.2) | (1.0) | |
| Strokea,b,c,e,f,g,h,i,j | 19.8 | 8.8 | 19.2 | 9.1 | 27.5 | 17.2 | 13.8 | 8.7 | 7.2 | 2.6 | 20.8 | 6.9 | 31.3 | 13.9 | 12.0 | 5.3 | 21.6 | 8.9 | 18.4 | 8.9 |
| (2.1) | (0.4) | (4.4) | (0.7) | (4.6) | (1.0) | (4.2) | (0.8) | (1.7) | (0.2) | (3.7) | (0.5) | (4.4) | (0.9) | (3.4) | (1.3) | (6.1) | (1.1) | (5.2) | (0.7) | |
Abbreviation: COURAGE Collaborative Research on Ageing in Europe; SAGE WHO Study on global AGEing and adult health; S. Africa South Africa
Data are % (SE). % is the percentage of individuals with sleep problems by the presence (Yes) or absence (No) of that chronic condition.
Difference between individuals with and without that chronic condition is statistically significant (P<0.05) in aOverall sample, bFinland, cPoland, dSpain, eChina, fGhana, gIndia, hMexico, iRussia, and jSouth Africa.
Association between chronic conditions (independent variable) and severe/extreme sleep problems (dependent variable) among adults aged 50 years or over estimated by logistic regression with multiple variables.
| COURAGE study | SAGE study | |||||||||
| Overall | Finland | Poland | Spain | China | Ghana | India | Mexico | Russia | S. Africa | |
| Angina | 2.02 | 2.78 | 2.36 | 1.78 | 1.75 | 1.92 | 1.91 | 1.84 | 2.49 | 2.20 |
| (1.70–2.40) | (1.55–4.96) | (1.60–3.47) | (1.12–2.83) | (1.22–2.51) | (1.35–2.72) | (1.44–2.52) | (0.72–4.70) | (1.52–4.07) | (1.25–3.88) | |
| Arthritis | 1.54 | 2.46 | 1.49 | 1.70 | 1.39 | 1.57 | 1.43 | 0.96 | 1.97 | 1.28 |
| (1.33–1.78) | (1.64–3.68) | (1.08–2.04) | (1.08–2.65) | (1.08–1.78) | (1.12–2.20) | (1.13–1.80) | (0.50–1.84) | (1.27–3.06) | (0.79–2.07) | |
| Asthma | 1.68 | 2.31 | 1.15 | 1.56 | 1.75 | 1.26 | 2.13 | 0.62 | 1.09 | 1.68 |
| (1.28–2.22) | (1.40–3.82) | (0.73–1.80) | (1.05–2.34) | (0.89–3.44) | (0.73–2.20) | (1.41–3.20) | (0.24–1.63) | (0.59–2.01) | (0.99–2.86) | |
| Chronic lung disease | 1.32 | 0.98 | 2.10 | 2.21 | 1.40 | 3.74 | 0.81 | 1.41 | 1.82 | 3.47 |
| (1.00–1.75) | (0.40–2.43) | (1.41–3.12) | (1.51–3.23) | (0.92–2.13) | (1.72–8.12) | (0.49–1.34) | (0.60–3.31) | (0.98–3.40) | (1.84–6.52) | |
| Depression | 2.36 | 2.62 | 2.22 | 4.03 | 4.63 | 1.75 | 1.94 | 5.12 | 3.15 | 3.44 |
| (1.95–2.86) | (1.60–4.28) | (1.58–3.12) | (2.91–5.59) | (2.76–7.77) | (1.02–3.01) | (1.45–2.58) | (2.42–10.83) | (1.97–5.06) | (1.27–9.30) | |
| Diabetes | 1.30 | 1.19 | 0.95 | 1.09 | 1.11 | 1.09 | 1.82 | 2.02 | 1.18 | 1.27 |
| (1.06–1.60) | (0.66–2.13) | (0.64–1.40) | (0.71–1.68) | (0.70–1.76) | (0.58–2.04) | (1.26–2.61) | (0.92–4.42) | (0.71–1.96) | (0.64–2.52) | |
| Hypertension | 1.12 | 1.50 | 1.20 | 1.10 | 0.77 | 0.97 | 1.24 | 1.38 | 1.03 | 0.96 |
| (0.95–1.32) | (0.88–2.55) | (0.84–1.71) | (0.78–1.56) | (0.56–1.06) | (0.72–1.31) | (0.98–1.56) | (0.68–2.80) | (0.64–1.66) | (0.60–1.52) | |
| Obesity | 1.05 | 0.68 | 1.21 | 1.18 | 1.08 | 1.38 | 0.67 | 0.56 | 1.11 | 0.92 |
| (0.86–1.27) | (0.41–1.15) | (0.84–1.73) | (0.82–1.71) | (0.66–1.78) | (0.90–2.13) | (0.38–1.21) | (0.28–1.14) | (0.73–1.70) | (0.59–1.41) | |
| Stroke | 1.81 | 1.72 | 1.26 | 0.57 | 2.11 | 2.14 | 2.35 | 1.68 | 1.66 | 1.49 |
| (1.34–2.44) | (0.86–3.42) | (0.68–2.35) | (0.27–1.21) | (1.14–3.91) | (1.17–3.91) | (1.43–3.84) | (0.71–3.99) | (0.94–2.94) | (0.47–4.74) | |
Abbreviation: COURAGE Collaborative Research on Ageing in Europe; SAGE WHO Study on global AGEing and adult health; S. Africa South Africa.
Data are Odds Ratio (95% Confidence Intervals).
All models are mutually adjusted for all chronic conditions in the model and age, sex, education, wealth, marital status, alcohol consumption, smoking, and physical activity. The model using the overall sample is also adjusted for county.
*p<0.05,
**p<0.01,
***p<0.001.
Association between number of chronic conditions (independent variable) and severe/extreme sleep problems (dependent variable) estimated by logistic regression with multiple variables.
| No. of chronic conditions | COURAGE study | SAGE study | ||||||||
| Overall | Finland | Poland | Spain | China | Ghana | India | Mexico | Russia | S. Africa | |
| 0 (Reference) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| 1 | 1.41 | 1.60 | 1.97 | 3.93 | 0.84 | 1.13 | 1.41 | 0.80 | 3.18 | 1.37 |
| (1.09–1.82) | (0.47–5.46) | (1.02–3.79) | (1.68–9.21) | (0.53–1.33) | (0.72–1.79) | (0.99–2.01) | (0.21–3.03) | (0.91–11.15) | (0.55–3.40) | |
| 2 | 2.55 | 3.03 | 2.65 | 4.94 | 1.60 | 2.17 | 2.91 | 2.00 | 5.01 | 1.79 |
| (1.99–3.27) | (0.88–10.47) | (1.35–5.20) | (2.01–12.17) | (1.00–2.55) | (1.36–3.47) | (2.09–4.07) | (0.61–6.56) | (1.30–19.26) | (0.69–4.67) | |
| 3 | 3.22 | 4.55 | 3.92 | 9.80 | 1.22 | 2.93 | 3.27 | 2.42 | 8.55 | 2.99 |
| (2.52–4.11) | (1.42–14.55) | (1.98–7.75) | (4.19–22.94) | (0.72–2.07) | (1.74–4.94) | (2.35–4.55) | (0.70–8.45) | (2.33–31.38) | (1.05–8.51) | |
| 4+ | 7.62 | 10.91 | 8.50 | 17.95 | 4.53 | 4.85 | 7.71 | 3.70 | 19.20 | 7.10 |
| (5.88–9.87) | (3.14–37.91) | (4.34–16.65) | (7.72–41.75) | (2.57–7.97) | (2.52–9.32) | (5.25–11.32) | (0.92–14.93) | (5.64–65.37) | (2.63-19.13) | |
Abbreviation: COURAGE Collaborative Research on Ageing in Europe; SAGE WHO Study on global AGEing and adult health; S. Africa South Africa.
Data are Odds Ratio (95% Confidence Intervals).
Trend test was significant for all regression analyses (p≤0.002).
All models are mutually adjusted for age, sex, education, wealth, marital status, alcohol consumption, smoking, and physical activity. The model using the overall sample is also adjusted for county.
*p<0.05,
**p<0.01,
***p<0.001.